New hope for lung cancer: targeted drug trial opens for patients with EGFR mutations

NCT ID NCT06905197

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 29 times

Summary

This study tests a new drug called DZD6008 in people with advanced non-small cell lung cancer that has certain EGFR gene changes. The main goals are to check the drug's safety and how well it shrinks tumors. About 140 adults will take part, and the drug is given by mouth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Blacktown Hospital
ACTIVE_NOT_RECRUITING

Blacktown, New South Wales, 2148, Australia
Chris O'Brien Lifehouse
NOT_YET_RECRUITING

Camperdown, New South Wales, 2050, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Herbert Irving Comprehensive Cancer Center
RECRUITING

New York, New York, 10032, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Virginia Cancer Specialist (NEXT Oncology-Virginia)
ACTIVE_NOT_RECRUITING

Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER